Rationale for the use of somatostatin analogs as antitumor agents

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1733-1742

  Susini, Cristiane ^a   Buscail, L ^a  

^a INSERM   (France)

Author keywords

Angiogenesis; Antitumor; Apoptosis; Receptor; Refractory tumor; Somatostatin analog

Indexed keywords

ANGIOPEPTIN; AUTOCRINE MOTILITY FACTOR; BIM 23244; BIM 23A387; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GROWTH HORMONE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LUTETIUM; METHOTREXATE; OCTREOTIDE; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN C; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; SURAMIN; UNINDEXED DRUG; VAPREOTIDE; VASCULOTROPIN; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOCRINE TUMOR; GASTROINTESTINAL TOXICITY; GENE THERAPY; HORMONE INHIBITION; HUMAN; HYPOPHYSIS TUMOR; ISOTOPE LABELING; MONOTHERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; SOMATOSTATIN;

EID: 33751001270     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl105     Document Type: Review

References (113)

1. Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35-50.
2. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973.
3. Redding TW, Schally AV. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 1983; 80: 1078-1082.
4. Lamberts SW, Reubi JC, Uiterlinden P et al. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology 1986; 118: 2188-2194.
5. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988; 48 (24 Pt 1): 6977-6985.
6. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993; 60: 245-264.
7. Moertel CG. Kamofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-1522.
8. Friess H, Buchler M, Beglinger C et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8: 540-545.
9. Shojamanesh H, Gibril F, Louie A et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-343.
10. di Bartolomeo M, Bajetta E, Buzzoni R et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77: 402-408.
11. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literature. J Surg Oncol 2002; 79: 180-187.
12. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
13. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002; 66: 161-183.
14. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001; 47 (Suppl 2): 30-39.
15. Gonzalez-Barcena D, Schally AV, Vadillo-Buenfil M et al. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate 2003; 56: 183-191.
16. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20: 348-367.
17. Bruns C, Lewis I, Briner U et al. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716.
18. Weckbecker G, Lewis I, Albert R et al. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003; 2: 999-1017.
19. Newman CB, Melmed S, George A et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040.
20. Colao A, Ferone D, Marzullo P et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86: 2779-2786.
21. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87: 3013-3018.
22. Cannavo S, Squadrito S, Curto L. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 2000; 32: 224-229.
23. Caron P, Arlot S, Bauters C et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001; 86: 2849-2853.
24. Cozzi R, Attanasio R, Montini M et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003; 88: 3090-3098.
25. Ben Shiomo A, Melmed S. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003; 88: 963-968.
26. Jaquet P, Saveanu A, Gunz G et al. Human somatostatin receptor subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. 2000; 85: 781-792.
27. Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat Rev Cancer 2004; 4: 285-295.
28. Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001; 47 (Suppl 2): 40-53.
29. Aparicio T, Ducreux M, Baudin E et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-1019.
30. Garland J, Buscombe JR, Bouvier C et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: A 3-year experience. Aliment Pharmacol Ther 2003; 17: 437-444.
31. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction? Int J Cancer 1994; 56: 681-688.
32. Kulaksiz H, Eissele R, Rossler D et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002; 50: 52-60.
33. Janson ET, Stridsberg M, Gobl A et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998; 58: 2375-2378.
34. Papotti M, Bongiovanni M, Volante M et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461-475.
35. Fjallskog ML, Ludvigsen E, Stridsberg M et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 59-67.
36. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793.
37. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002; 87: 4142-4146.
38. Bevan JS, Atkin SL, Atkinson AB et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87: 4554-4563.
39. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg 1996; 20: 203-207.
40. Ricci S, Antonuzzo A, Galli L et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000; 11: 1127-1130.
41. Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985; 109: 108-114.
42. Brevini TA, Bianchi R, Motta M. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: Possible mechanism of action. J Clin Endocrinol Metab 1993; 77: 626-631.
43. Siegel RA, Tolesvai L, Rudin M. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin ISMS 201-995). Cancer Res 1988; 48: 4651-4655.
44. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999; 59: 1947-1953.
45. Szende B, Keri G. TT-232: A somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs 2003; 14: 585-588.
46. Keri G, Erchegyi J, Horvath A et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci USA 1996; 93: 12513-12518.
47. Pinski J, Schally AV, Halmos G et al. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer 1996; 65: 870-874.
48. Schally AV, Szepeshazi K, Nagy A et al. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004; 61: 1042-1068.
49. Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann NY Acad Sci 2004; 1014: 121-131.
50. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-1696.
51. Pages P, Benali N, Saint-Laurent N et al. sst2 somatoslatin receptor mediates cell cycle arrest and induction of p27(Kip1), Evidence for the role of SHP-1. J Biol Chem 1999; 274: 15186-15193.
52. Cattaneo MG, Taylor JE, Culler MD, Nisoli E, Vicentini LM. Selective stimulation of somatostatin receptor subtypes: Differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 2000; 481: 271-276.
53. Florio T, Morini M, Villa V et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003; 144: 1574-1584.
54. Smalley KS, Feniuk W, Sellers LA, Humphrey PP, The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification. Biochem Biophys Res Commun 1999; 263: 239-243.
55. Lahlou H, Fanjul M, Pradayrol L et al. Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol 2005; 25: 4034-4045.
56. Buscail L, Saint-Laurent N, Chastre E et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56: 1823-1827.
57. Delesque N, Buscail L, Esteve JP et al. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997; 57: 956-962.
58. Rochaix P, Delesque N, Esteve JP et al. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999; 10: 995-1008.
59. Benali N, Cordelier P, Calise D et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000; 97: 9180-9185.
60. Shimon I, Taylor JE, Dong JZ et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-798.
61. Rocheville M, Lange DC, Kumar U et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275: 7862-7869.
62. Patel RC, Kumar U, Lamb DC et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 2002; 99: 3294-3299.
63. Pfeiffer M, Koch T, Schroder H et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2001; 276: 14027-14036.
64. Saveanu A, Gunz G, Dufour H et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86: 140-145.
65. Ren SG, Kim S, Taylor J et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003; 88: 5414-5421.
66. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24: 28-47.
67. Froidevaux S, Hintermann E, Torok M et al. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 1999; 59: 3652-3657.
68. Bruno JF, Xu Y, Berelowitz M. Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells. Biochem Biophys Res Commun 1994; 202: 1738-1743.
69. Reubi JC, Kvols LK, Weser B et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5977.
70. Sarret P, Esdaile MJ, McPherson PS et al. Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells. J Biol Chem 2004; 279: 8029-8037.
71. Tulipano G, Bonfanti C, Milani G et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001; 73: 344-351.
72. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors, Neuroendocrinology 2004; 80 (Suppl 1): 47-50.
73. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/ insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002; 143: 4123-4130.
74. Murray RD, Kim K, Ren SG et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004; 89: 3027-3032.
75. Hofland LJ, van der Hoek J, van Koetsveld PM et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004; 89: 1577-1585.
76. Murray RD, Kim K, Ren SG et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004; 114: 349-356.
77. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
78. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: A review and future perspectives. Cancer Biother Radiopharm 2003; 18: 601-609.
79. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-846.
80. Danesi R, Agen C, Benelli U et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997; 3: 265-272.
81. Woltering EA, Watson JC, Alperin-Lea RC et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997; 15: 77-86.
82. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000; 268(2): 567-71.
83. Barrie R, Woltering EA, Hajarizadeh H et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993; 55: 446-450.
84. Treiber G, Wex T, Malfertheiner P. Inhibition of angiogenesis rather than growth hormones is a key factor for ocreotide treatment response in HCC patients. Proc ASCO 2004; Abstr 91.
85. Adams RL, Adams IP, Lindow SW, Atkin SL. Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin Endocrinol (Oxf) 2004; 61: 431-436.
86. Arena S, Pattarozzi A, Corsaro A, Schettini G, Florio T. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol Endocrinol 2005; 19: 255-267.
87. Jia WD, Xu GL, Sun HC et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis Int 2003; 2: 404-409.
88. Kumar M, Liu ZR, Thapa L et al. Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol 2004; 10: 393-399.
89. Hayry P, Raisanen A, Ustinov J et al. Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. Faseb J 1993; 7: 1055-1060.
90. Bhathena SJ, Louie J, Schechter GP et al. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127-131.
91. Ferone D, van Hagen PM, Semino C et al. Somatostatin receptor distribution and function in immune system. Dig Liver Dis 2004; 36 (Suppl 1): 68-77.
92. Dalm VA, Hofland LJ, Ferone D et al. The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. J Endocrinol Invest 2003; 26 (8 Suppl): 94-102.
93. Elliott DE, Li J, Blum AM. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999; 29: 2454-2463.
94. Peluso G, Petillo O, Melone MA et al. Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996; 30: 443-451.
95. Ritts RE, Kvols L, Strehlo B et al. Immunologic studies of patients with malignant neuroendocrine carcinomas and responses to somatostatin analog (SMS 201-995, Sandostatin). Dallas, TX: 1989.
96. Rosskopf D, Schurks M, Manthey I et al. Signal transduction of somatostatin in human B lymphoblasts. Am J Physiol Cell Physiol 2003; 284: 179-190.
97. Lattuada D, Casnici C, Venuto A, Marelli O. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. J Neuroimmunol 2002; 133: 211-216.
98. Lamberts SW, van Koetsveld P, Hofland LJ. The interrelationship between the anti-mitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin. Int J Cancer 1991; 48: 938-941.
99. Szepeshazi K, Schally AV, Nagy A et al. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003; 98: 1401-1410.
100. Kiaris H, Schally AV, Nagy A et al. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer 2001; 37: 620-628.
101. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial. J Clin Oncol 1993; 11(1): 148-51.
102. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999; 26: 1439-1447.
103. Paganelli G, Bodei L, Handkiewicz Junak D et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66: 393-398.
104. Vernejoul F, Faure P, Benali N et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002; 62: 6124-6131.
105. Rogers BE, Zinn KR, Lin CY et al. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer 2002; 94 (4 Suppl): 1298-1305.
106. Reubi JC, Schaer JC, Waser B et al. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur J Pharmacol 1998; 345: 103-110.
107. Le Romancer M, Reyl-Desmars F, Cherifi Y et al. The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity. J Biol Chem 1994; 269: 17464-17468.
108. Held-Feindt J, Forstreuter F, Pufe T, Mentlein R. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res Mol Brain Res 2001; 87: 12-21.
109. Lopez F, Esteve JP, Buscail L et al. The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J Biol Chem 1997; 272: 24448-24454.
110. Cordelier P, Esteve JP, Bousquet C et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA 1997; 94: 9343-9348.
111. Lin CY, Varma MG, Joubel A et al. Conserved motifs in somatostatin, D2-dopamine, and alpha 2B-adrenergic receptors for inhibiting the Na-H exchanger, NHE1. J Biol Chem 2003; 278: 15128-15135.
112. Sharma K, Srikant CB. G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification. Biochem Biophys Res Commun 1998; 242: 134-140.
113. Guillermet J, Saint-Laurent N, Rochaix P et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 2003; 100: 155-160.